Status: Recruiting

Food-Effect, Single and Multiple Dose Pharmacokinetics, Safety and Tolerability Study of 4-MUST, 128 mg, Tablets in Healthy Volunteers

This open-label study will evaluate the effect of food on the bioavailability of a single dose of 4-MUST, tablets, 128 mg. Additionally, the study will assess the pharmacokinetics, safety, and tolerability of 4-MUST, tablets, 128 mg following both single and multiple oral dose administration.

Participants needed: 45

Trial details

Phase: Phase 1Age: 18-45Biological sex: AllType: InterventionalSponsor: Valenta Pharm JSCUpdated: Jun 15, 2026Locations: 1

Eligibility criteria

Voluntary, personally signed ICF obtained prior to any study procedures; [+37]

Voluntary withdrawal of the subject from the study; [+11]

Status: Recruiting

Efficacy, Safety, and Tolerability of 4-MUST, 128 mg Tablets in Chronic Cholecystitis and Biliary Dyskinesia

The aim of the study is to evaluate the efficacy, safety, and tolerability of 4-MUST, 128 mg tablets compared to placebo in patients with chronic cholecystitis and biliary dyskinesia.

Participants needed: 300

Trial details

Phase: Phase 3Age: 18-70Biological sex: AllType: InterventionalSponsor: Valenta Pharm JSCUpdated: May 19, 2026Locations: 10

Eligibility criteria

Males and females aged 18-70 years. [+43]

Incorrect enrollment of a patient in the study (failure to meet inclusion/exclus... [+11]

Status: Recruiting

Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 mg Tablets in Healthy Volunteers.

This study aims to evaluate pharmacokinetic profile, safety and establish bioequivalence of the investigational drug Trimedat® 76,95 mg orally disintegrating tablets compared to the reference drug Trimedat® 100 mg tablets in healthy volunteers under fasted conditions.

Participants needed: 36

Trial details

Phase: Phase 1Age: 18-45Biological sex: AllType: InterventionalSponsor: Valenta Pharm JSCUpdated: Feb 19, 2026Locations: 1

Eligibility criteria

Voluntarily and personally signed informed consent form by a healthy volunteer o... [+37]

Withdrawal of the volunteer from further participation in the study; [+11]

Status: Recruiting

Efficacy, Safety, and Tolerability of 4-MUST Tablets in Chronic Cholecystitis and Biliary Dyskinesia

This study aims to evaluate the efficacy, safety, and tolerability of the drug 4-MUST at various doses compared to placebo in patients with chronic cholecystitis and biliary dyskinesia

Participants needed: 300

Trial details

Phase: Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: Valenta Pharm JSCUpdated: Jul 11, 2025Locations: 17

Eligibility criteria

Males and females aged 18-70 years. [+39]

Incorrect enrollment of a patient in the study (failure to meet inclusion/exclus... [+10]